Intuitive Surgical, Inc. (ISRG)
ISRG vs. MDT: Which Robotic Surgery Stock Is a Smarter Buy Now?
Intuitive Surgical or Medtronic -- who leads the future of robotic surgery? Here's a comparative analysis to help you make a smart choice for 2025.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Intuitive Surgical (ISRG). This makes it worthwhile to examine what the stock has in store.
Intuitive Surgical: Moat, Resilience But High Market Expectations
Intuitive Surgical remains a dominant leader in robotic surgery with strong recurring revenues, high switching costs, and robust financial health. Business fundamentals are excellent, with resilient procedure growth, innovation momentum, and a healthy balance sheet with no long-term debt. Valuation is the main concern: ISRG trades at a significant premium to peers and its own history, pricing in near-perfect execution.
Intuitive Surgical: The Business Model Of Robotic Surgery Supports A Bullish Outlook
Intuitive Surgical's share price has rebounded after a sharp drop, driven by strong Q1 2025 results and easing tariff concerns, with further upside expected. As the dominant leader in robotic surgery, ISRG benefits from its first-mover advantage, technological leadership, and a sticky ecosystem that drives recurring revenue. The da Vinci 5 system, rising surgical volumes, and a new subscription model position ISRG for accelerated growth, especially in emerging markets.
ISRG Stock Gains More than 8% YTD: Will the Uptrend Continue?
Shares of Intuitive Surgical ISRG seem to gain momentum after declining for more than two months. The stock has risen 9.7% in the past month after declining more than 30% from its all-time high of $616 in January.
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Trade Tracker: Stephanie Link sells Eli Lilly and buys more Intuitive Surgical
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves.
2 Stocks I Can't Wait to Buy During the Next Market Correction
Investors never know when the next market correction -- a drop of from 10% to 20% in an index -- is coming, but we know that it will eventually happen. And because that's true, it makes sense to make a list of the stocks you'd like to buy if they dip during a correction.
Trump's Tariffs Could Impact This Top Growth Stock. Here's Why It's Still a Buy
President Donald Trump's macroeconomic policies are creating significant uncertainty. His decision to impose sweeping tariffs on goods imported into the U.S. could harm the economy and specific corporations in ways that are scaring off investors.
ISRG vs. SYK: Which Robotic-Device Innovator Is a Better Buy?
As robotic-assisted surgery becomes a cornerstone of modern healthcare, two medtech giants — Intuitive Surgical ISRG and Stryker SYK — are leading the charge. Intuitive, the pioneer behind the da Vinci Surgical System, has long dominated soft tissue procedures.
Intuitive Surgical, Inc. (ISRG) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Intuitive Surgical (ISRG) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Intuitive Surgical: Decent Results But Waiting For An Entry Point
Intuitive Surgical's Q1 2025 earnings showed mixed results, with revenue and EPS beating expectations, but gross margins impacted by tariffs and a lower-margin product mix. Procedure volume growth was strong, especially outside the US, and management raised full-year growth targets, indicating optimism despite macroeconomic uncertainties. The company's valuation is high, trading at 60x forward P/E, making it expensive; I'm looking for a lower entry point around 45x forward P/E.
